Lamont et al. also suggest focussing on the
development of a vaccine to tackle these complex pathological processes
in pregnancies at risk of adverse outcomes.1Unfortunately, such a vaccine is not yet available, and the issues
concerning IAP will also be present in vaccine implementation, e.g. the
selection of a population and timing of
prophylaxis/immunisation.4